These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2583953)

  • 21. Hypothalamic-mediated immune mechanisms and their relevance to the pathoetiology of Parkinson's disease.
    Sandyk R; Iacono RP
    Int J Neurosci; 1987 Feb; 32(3-4):979-81. PubMed ID: 3596940
    [No Abstract]   [Full Text] [Related]  

  • 22. Editorial: Brain-Targeted Autoimmunity: Beyond Multiple Sclerosis.
    Nataf S; Hunot S; Dorothée G; Liblau R
    Front Immunol; 2021; 12():677577. PubMed ID: 33868319
    [No Abstract]   [Full Text] [Related]  

  • 23. Augmentation of Autoantibodies by Helicobacter pylori in Parkinson's Disease Patients May Be Linked to Greater Severity.
    Suwarnalata G; Tan AH; Isa H; Gudimella R; Anwar A; Loke MF; Mahadeva S; Lim SY; Vadivelu J
    PLoS One; 2016; 11(4):e0153725. PubMed ID: 27100827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Naturally Occurring Autoantibodies against Tau Protein Are Reduced in Parkinson's Disease Dementia.
    Kronimus Y; Albus A; Balzer-Geldsetzer M; Straub S; Semler E; Otto M; Klotsche J; Dodel R; ; Mengel D
    PLoS One; 2016; 11(11):e0164953. PubMed ID: 27802290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypothalamic-locus coeruleus mechanisms in the pathophysiology of "on-off" in L-dopa treated Parkinson's disease: a hypothesis.
    Sandyk R
    Int J Neurosci; 1989 Aug; 47(3-4):303-8. PubMed ID: 2681032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Surgical therapy for Parkinson's disease].
    Tomita S; Date I; Ohmoto T
    No To Shinkei; 2000 Nov; 52(11):947-58. PubMed ID: 11215268
    [No Abstract]   [Full Text] [Related]  

  • 27. Hypothalamic compensatory mechanisms in Parkinson's disease.
    Sandyk R
    Int J Neurosci; 1989 Jan; 44(1-2):135-42. PubMed ID: 2485819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential utility of autoantibodies as blood-based biomarkers for early detection and diagnosis of Parkinson's disease.
    DeMarshall CA; Han M; Nagele EP; Sarkar A; Acharya NK; Godsey G; Goldwaser EL; Kosciuk M; Thayasivam U; Belinka B; Nagele RG;
    Immunol Lett; 2015 Nov; 168(1):80-8. PubMed ID: 26386375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease.
    Drouin-Ouellet J; St-Amour I; Saint-Pierre M; Lamontagne-Proulx J; Kriz J; Barker RA; Cicchetti F
    Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25522431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune functions in Parkinson's disease lymphocyte subsets, concanavalin A-induced suppressor cell activity and in vitro immunoglobulin production.
    Marttila RJ; Eskola J; Soppi E; Rinne UK
    J Neurol Sci; 1985 Jul; 69(3):121-31. PubMed ID: 3161999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease.
    Mann VM; Cooper JM; Krige D; Daniel SE; Schapira AH; Marsden CD
    Brain; 1992 Apr; 115 ( Pt 2)():333-42. PubMed ID: 1606472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Selected aspects of immunological disorders in Parkinson disease].
    Fiszer U
    Neurol Neurochir Pol; 2004; 38(1 Suppl 1):S63-6. PubMed ID: 15045870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glial cell response: A pathogenic factor in Parkinson's disease.
    Wu DC; Tieu K; Cohen O; Choi DK; Vila M; Jackson-Lewis V; Teismann P; Przedborski S
    J Neurovirol; 2002 Dec; 8(6):551-8. PubMed ID: 12476349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Humoral response against small heat shock proteins in Parkinson's disease.
    Papuć E; Kurys-Denis E; Krupski W; Rejdak K
    PLoS One; 2015; 10(1):e0115480. PubMed ID: 25629316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroimmune mechanisms in Parkinson's disease.
    Kuhn W; Müller T
    J Neural Transm Suppl; 1995; 46():229-33. PubMed ID: 8821059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation.
    George S; Brundin P
    J Parkinsons Dis; 2015; 5(3):413-24. PubMed ID: 26406122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parkinsonism in Caplan's syndrome.
    Rizzo G; Scaglione C; Lopane G; Pollini A; Tommasoni E; Martinelli P
    Neurol Sci; 2006 Apr; 27(1):67-9. PubMed ID: 16688603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Experimental modeling of preclinical and clinical stages of Parkinson's disease.
    Khaindrava VG; Kozina EA; Kudrin VS; Kucheryanu VG; Klodt PD; Narkevich VB; Bocharov EV; Nanaev AK; Kryzhanovsky GN; Raevskii KS; Ugrumov MV
    Bull Exp Biol Med; 2011 Mar; 150(5):566-9. PubMed ID: 22235385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathogenesis of Parkinson's disease: oxidative stress, environmental impact factors and inflammatory processes.
    Yuan H; Zheng JC; Liu P; Zhang SF; Xu JY; Bai LM
    Neurosci Bull; 2007 Mar; 23(2):125-30. PubMed ID: 17592536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glutamate and Parkinson's disease.
    Greenberg DA
    Ann Neurol; 1994 Jun; 35(6):639. PubMed ID: 7911652
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.